UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000019090
Receipt number R000022073
Scientific Title Reduced form of CoenzymeQ10 for Parkinson's disease - open trial of dose finding test and combination with hydrogen water
Date of disclosure of the study information 2015/11/01
Last modified on 2017/01/25 16:59:13

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Reduced form of CoenzymeQ10 for Parkinson's disease - open trial of dose finding test and combination with hydrogen water

Acronym

Dose finding test of reduced form of Coenzyme Q10 for Parkinson's disease

Scientific Title

Reduced form of CoenzymeQ10 for Parkinson's disease - open trial of dose finding test and combination with hydrogen water

Scientific Title:Acronym

Dose finding test of reduced form of Coenzyme Q10 for Parkinson's disease

Region

Japan


Condition

Condition

Parkinson's disease

Classification by specialty

Neurology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Dose finding test of Coenzyme Q10 and combination study of hydrogen water

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The differences from baseline to 16th week of MDS-UPDRS part III and plasma % coenzyme Q10(CoQ10)

Key secondary outcomes

The differences of each parts or total of MDS-UPDRS
The differences of urine 18OH-dG
The differences of plasma reduced form of CoQ10


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Dose comparison

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

reduced form of CoQ10 300mg 16weeks

Interventions/Control_2

reduced form of CoQ10 600mg 16weeks

Interventions/Control_3

reduced form of CoQ10 600mg 16weeks
hydrogen water 500ml(Suisosui 7.0) 16weeks

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

diagnosed as PD conforming to the United Kingdom Brain Bank criteria
treated with levodopa
the same anti-parkinsonian drug regimen for at least 8 weeks prior to baseline assessment
modified Hoehn and Yahr stage 1~3
twenty to eighty years old
without dementia
written informed consent was obtained

Key exclusion criteria

presence of parkinsonism unrelated to PD, dementia or other serious disease, malignant tumor, a history of brain surgery, and adverse events caused by medications.
modified Hoehn and Yahr stage 4 and 5
without allergy for medication

Target sample size

45


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Asako Yoritaka

Organization

Juntendo University Koshigaya Hospital

Division name

Neurology

Zip code


Address

Fukuroyama 560, Koshigaya-shi, Saitama Japan

TEL

048-975-0321

Email

ayori@juntendo.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Asako Yoritaka

Organization

Neurology

Division name

Juntendo University Koshigaya Hospital

Zip code


Address

Fukuroyama 560, Koshigaya-shi, Saitama Japan

TEL

048-975-0321

Homepage URL


Email

ayori@juntendo.ac.jp


Sponsor or person

Institute

Juntendo University Koshigaya Hospital

Institute

Department

Personal name



Funding Source

Organization

Department of Neurology, Juntendo University Koshigaya Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 11 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 11 Month 01 Day

Date of IRB


Anticipated trial start date

2015 Year 11 Month 04 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 09 Month 22 Day

Last modified on

2017 Year 01 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022073


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name